Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Sold by Trexquant Investment LP

Trexquant Investment LP decreased its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 51.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 44,024 shares of the biopharmaceutical company's stock after selling 46,719 shares during the period. Trexquant Investment LP's holdings in Alnylam Pharmaceuticals were worth $10,359,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Larson Financial Group LLC lifted its stake in Alnylam Pharmaceuticals by 187.2% during the 4th quarter. Larson Financial Group LLC now owns 112 shares of the biopharmaceutical company's stock valued at $26,000 after acquiring an additional 73 shares during the period. R Squared Ltd bought a new stake in Alnylam Pharmaceuticals in the 4th quarter worth approximately $33,000. OFI Invest Asset Management purchased a new stake in Alnylam Pharmaceuticals during the 4th quarter valued at $35,000. Versant Capital Management Inc boosted its stake in shares of Alnylam Pharmaceuticals by 77.6% in the 4th quarter. Versant Capital Management Inc now owns 190 shares of the biopharmaceutical company's stock worth $45,000 after buying an additional 83 shares during the last quarter. Finally, Quantbot Technologies LP boosted its position in Alnylam Pharmaceuticals by 1,754.5% in the third quarter. Quantbot Technologies LP now owns 204 shares of the biopharmaceutical company's stock worth $56,000 after purchasing an additional 193 shares during the last quarter. 92.97% of the stock is owned by institutional investors.

Remove Ads

Insider Buying and Selling at Alnylam Pharmaceuticals

In other news, CMO Pushkal Garg sold 52,592 shares of the business's stock in a transaction dated Monday, January 27th. The stock was sold at an average price of $285.00, for a total value of $14,988,720.00. Following the completion of the sale, the chief marketing officer now directly owns 11,989 shares of the company's stock, valued at approximately $3,416,865. The trade was a 81.44 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Jeffrey V. Poulton sold 967 shares of the firm's stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $255.17, for a total value of $246,749.39. Following the transaction, the chief financial officer now owns 32,786 shares in the company, valued at $8,366,003.62. This represents a 2.86 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 71,234 shares of company stock worth $19,958,097 over the last three months. Insiders own 1.50% of the company's stock.

Analyst Upgrades and Downgrades

ALNY has been the subject of a number of recent research reports. Citigroup boosted their price objective on shares of Alnylam Pharmaceuticals from $338.00 to $351.00 and gave the company a "buy" rating in a research report on Friday, March 21st. Scotiabank increased their price objective on shares of Alnylam Pharmaceuticals from $338.00 to $342.00 and gave the stock a "sector outperform" rating in a research note on Monday, March 31st. Stifel Nicolaus lifted their target price on shares of Alnylam Pharmaceuticals from $300.00 to $345.00 and gave the company a "buy" rating in a research note on Monday, March 31st. Chardan Capital restated a "buy" rating and set a $300.00 target price on shares of Alnylam Pharmaceuticals in a research report on Friday, March 21st. Finally, Redburn Atlantic initiated coverage on shares of Alnylam Pharmaceuticals in a report on Monday, March 31st. They set a "buy" rating and a $353.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and twenty-one have assigned a buy rating to the company's stock. According to MarketBeat.com, Alnylam Pharmaceuticals has an average rating of "Moderate Buy" and an average price target of $316.25.

Alnylam Pharmaceuticals Price Performance

Shares of NASDAQ ALNY traded down $4.17 during trading on Monday, hitting $231.57. The company had a trading volume of 678,782 shares, compared to its average volume of 844,120. The firm has a market capitalization of $30.12 billion, a price-to-earnings ratio of -106.14 and a beta of 0.30. The company has a quick ratio of 2.71, a current ratio of 2.78 and a debt-to-equity ratio of 15.27. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $141.98 and a fifty-two week high of $304.39. The stock has a fifty day simple moving average of $259.03 and a two-hundred day simple moving average of $260.14.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.62) by ($0.03). On average, research analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.